Monopar Therapeutics Inc (MNPR) Price & Analysis

Compare

546 Followers

MNPR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.50 - $81.89

Previous CloseN/A

Volume23.12K

Average Volume (3M)57.33K

Market Cap

$468.30M

Enterprise Value$197.25M

Total Cash (Recent Filing)$39.50B

Total Debt (Recent Filing)$80.37M

Price to Earnings (P/E)―

Beta2.04

Next Earnings

Nov 07, 2025

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding6,169,961

10 Day Avg. Volume86,368

30 Day Avg. Volume57,332

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.51

Price to Sales (P/S)0.00

P/FCF Ratio-13.02

Enterprise Value/Market Cap0.42

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-11.39

Forecast

1Y Price Target

$99.11

Price Target Upside16.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyALXN1840 may displace trientine and zinc in subsets of patients and eventually compete for first-line use in newly diagnosed cases due to its superior copper mobilization and convenient once-daily oral dosing.

Market PositionThe data position ALXN1840 as a potential step-change therapy for Wilson disease, offering a significant therapeutic advance for the first time in over three decades.

Safety And TolerabilitySafety and tolerability continue to look clean: In total, the safety analysis of 266 patients demonstrated 13 (4.9%) any drug-related serious adverse events.

Bears Say

Regulatory RiskThere is still a modest risk that the FDA may ask for another copper balance study for further validation.

Monopar Therapeutics Inc News

Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer

Oppenheimer raised the firm’s price target on Monopar Therapeutics (MNPR) to $115 from $77 and keeps an Outperform...

17h ago

AZN

MNPR

Monopar Therapeutics price target raised to $105 from $70 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $105 from $70 and keeps a...

4d ago

MNPR

Monopar Therapeutics price target raised to $85 from $60 at Chardan

Chardan analyst Keay Nakae raised the firm’s price target on Monopar Therapeutics (MNPR) to $85 from $60 and...

8d ago

MNPR

Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler

Piper Sandler analyst Biren Amin raised the firm’s price target on Monopar Therapeutics (MNPR) to $95 from $76...

8d ago

MNPR

Monopar Therapeutics price target raised to $104 from $87 at BTIG

BTIG raised the firm’s price target on Monopar Therapeutics (MNPR) to $104 from $87 and keeps a Buy...

8d ago

AZN

MNPR

Monopar jumps after doctor letter in Journal of Hepatology

Monopar Therapeutics (MNPR) earlier today announced that the Journal of Hepatology published a peer-reviewed letter to the editor,...

9d ago

MNPR

Monopar Therapeutics price target raised to $109 from $74 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Monopar Therapeutics (MNPR) to $109 from $74 and keeps an...

9d ago

MNPR

CoreWeave upgraded, Lululemon downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

10d ago

DKS

JNJ

Monopar Therapeutics initiated with a Buy at Lake Street

Lake Street initiated coverage of Monopar Therapeutics (MNPR) with a Buy rating and $106 price target Monopar is...

10d ago

MNPR

Monopar Therapeutics management to meet virtually with Piper Sandler

Virtual Meeting to be held on September 24 hosted by Piper Sandler. Published first on TheFly – the...

10d ago

MNPR

Monopar Therapeutics Announces Underwriting Agreement for Stock Sale

Monopar Therapeutics Inc ( ($MNPR) ) has shared an update. On September 23, 2025, Monopar Therapeutics Inc. entered...

8d ago

MNPR

Positive Outlook for Monopar Therapeutics’ ALXN1840 Amid New Copper Balance Findings

Analyst Jeet Mukherjee from BTIG reiterated a Buy rating on Monopar Therapeutics Inc and increased the price target...

8d ago

MNPR

Promising Long-Term Efficacy and Safety of ALXN1840 Strengthens Buy Rating for Monopar Therapeutics Inc.

BTIG analyst Jeet Mukherjee has reiterated their bullish stance on MNPR stock, giving a Buy rating yesterday. Jeet...

17d ago

MNPR

Monopar Therapeutics Presents New Data on ALXN1840

An announcement from Monopar Therapeutics Inc ( ($MNPR) ) is now available. On September 14, 2025, Monopar Therapeutics...

18d ago

MNPR

MNPR FAQ

What was Monopar Therapeutics Inc’s price range in the past 12 months?

Monopar Therapeutics Inc lowest stock price was $4.50 and its highest was $81.89 in the past 12 months.

What is Monopar Therapeutics Inc’s market cap?

Monopar Therapeutics Inc’s market cap is $468.30M.

When is Monopar Therapeutics Inc’s upcoming earnings report date?

Monopar Therapeutics Inc’s upcoming earnings report date is Nov 07, 2025 which is in 35 days.

How were Monopar Therapeutics Inc’s earnings last quarter?

Monopar Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.458 by $0.108.

Is Monopar Therapeutics Inc overvalued?

According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Monopar Therapeutics Inc pay dividends?

Monopar Therapeutics Inc does not currently pay dividends.

What is Monopar Therapeutics Inc’s EPS estimate?

Monopar Therapeutics Inc’s EPS estimate is -0.41.

How many shares outstanding does Monopar Therapeutics Inc have?

Monopar Therapeutics Inc has 6,169,961 shares outstanding.

What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?

Monopar Therapeutics Inc reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.458. Following the earnings report the stock price went up 14.55%.

Which hedge fund is a major shareholder of Monopar Therapeutics Inc?

Currently, no hedge funds are holding shares in MNPR

Monopar Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-59.38%

Trailing 12-Months

Asset Growth

650.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Monopar Therapeutics Inc

Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for cancer patients. The company operates within the biotechnology and pharmaceuticals sectors, concentrating its efforts on advancing a pipeline of proprietary oncology drug candidates. Its core product candidates include therapies targeting severe side effects of chemotherapy and novel approaches to treat various types of cancer.

Monopar Therapeutics Inc (MNPR) Earnings & Revenues

Historic Earnings Reports

MNPR Stock 12 Month Forecast

Average Price Target

$99.11

▲(16.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","116":"$116","29.75":"$29.8","58.5":"$58.5","87.25":"$87.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":99.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$99.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,29.75,58.5,87.25,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.73,87.05846153846154,89.38692307692308,91.71538461538462,94.04384615384616,96.3723076923077,98.70076923076924,101.02923076923076,103.3576923076923,105.68615384615384,108.01461538461538,110.34307692307692,112.67153846153846,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.73,85.83615384615385,86.9423076923077,88.04846153846154,89.15461538461538,90.26076923076923,91.36692307692309,92.47307692307693,93.57923076923078,94.68538461538462,95.79153846153847,96.89769230769231,98.00384615384615,{"y":99.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.73,84.36615384615385,84.0023076923077,83.63846153846154,83.27461538461539,82.91076923076923,82.54692307692308,82.18307692307692,81.81923076923077,81.45538461538462,81.09153846153846,80.72769230769231,80.36384615384615,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.93,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >